IRF5

Across TCGA pan-cancer cohorts, IRF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IRF5 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IRF5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IRF5 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and COAD are the cancer types where IRF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.442	0.925	.004	16	view →
HNSC	DFS	Tertile	III,IV	0.903	0.305	.008	13	view →
COAD	DFS	Median	III,IV	0.622	1.000	.030	6	view →
PDAC	DFS	Quartile	II,III,IV	0.621	0.832	.004	5	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IRF5–LUAD (DFS)

Open the LUAD breakdown →